A Brazilian study on the use of proxalutamide, a new drug indicated for prostate cancer, provided unexpected benefits for hospitalized patients with COVID-19. Results showed that 81% of patients with COVID-19 who received proxalutamide for…

Sandra Horne, DHA, MHSA, RDH, adapts her educational approach to ensure her students receive the necessary training during COVID-19.

Scientists strategize to disrupt stubborn bacteria-yeast biofilm implicated in early childhood caries.

Study shows that individuals with periodontal diseases are likely to pass the SARS-CoV-2 virus from their saliva into their lungs—with potentially deadly results.

New research from the National Institutes of Health has found that the immunity acquired from COVID-19 vaccination seems to be more adept at creating antibodies to a wide spectrum of SARS-CoV-2 variants than the immunity gained…

Individuals who experience migraine headaches may be at increased risk of contracting COVID-19 or suffer more severe symptoms, according to research presented at the annual meeting of the American Headache Society. Data from more than 170…

More than 20 million young people in the United States have been vaccinated against COVID-19, and the US Centers for Disease Control and Prevention has found 300 cases of myocarditis or pericarditis among this population following…

Fluoride varnish has become a widely utilized, professional topical application for treating dentinal hypersensitivity and preventing caries. While fluoride varnish has United States Food and Drug Administration approval for treating…

Delta, the newest and most virulent COVID-19 variant that has ravaged India, is quickly spreading around the globe. Unfortunately, this variant causes twice as many hospitalizations as previous iterations of the novel coronavirus, according…

The United States Department of Health and Human Services is spending more than $3 billion to develop anti-viral pills to treat COVID-19. The significant financial commitment will support clinical trials of three potentially viable…